|
1.
|
Husaini B, Levine R, Sharp L, Cain V, Novotny M, Hull P, Orum G, Samad Z, Sampson U, Moonis M. Depression increases stroke hospitalization cost: an analysis of 17,010 stroke patients in 2008 by race and gender. Stroke Res Treat. 2013; 2013:846732.
|
|
|
|
|
2.
|
Henninger N, Lin E, Haussen DC, Lehman LL, Takhtani D, Selim M, Moonis M. Leukoaraiosis and sex predict the hyperacute ischemic core volume. Stroke. 2013 Jan; 44(1):61-7.
|
|
|
|
|
3.
|
Fisher M, Moonis M. Neuroprotective effects of statins: evidence from preclinical and clinical studies. Curr Treat Options Cardiovasc Med. 2012 Jun; 14(3):252-9.
|
|
|
|
|
4.
|
Moonis M. High-dose statins should be used in all acute ischemic strokes. Stroke. 2012 Jul; 43(7):1992-3.
|
|
|
|
|
5.
|
Henninger N, Lin E, Baker SP, Wakhloo AK, Takhtani D, Moonis M. Leukoaraiosis predicts poor 90-day outcome after acute large cerebral artery occlusion. Cerebrovasc Dis. 2012; 33(6):525-31.
|
|
|
|
|
6.
|
Cachia D, Swearer J, Ferguson W, Moonis M. Selective cognitive patterns resulting from bilateral hippocampal ischemia. Arch Med Sci. 2011 Feb; 7(1):168-72.
|
|
|
|
|
7.
|
Dangayach NS, Kane K, Moonis M. Paroxysmal atrial fibrillation in cryptogenic stroke. Ther Clin Risk Manag. 2011; 7:33-7.
|
|
|
|
|
8.
|
Pollen DA, Baker S, Hinerfeld D, Swearer J, Evans BA, Evans JE, Caselli R, Rogaeva E, St George-Hyslop P, Moonis M. Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4. Alzheimers Res Ther. 2010; 2(5):31.
|
|
|
|
|
9.
|
Lin E, Padmanabhan R, Moonis M. Antiplatelet agents and proton pump inhibitors - personalizing treatment. Pharmgenomics Pers Med. 2010; 3:101-9.
|
|
|
|
|
10.
|
Titelbaum DS, Sodha NB, Moonis M. Transient hemiglossal denervation during acute internal capsule infarct in the setting of dysarthria-clumsy hand syndrome. AJNR Am J Neuroradiol. 2010 Aug; 31(7):1266-7.
|
|
|
|
|
11.
|
Henninger N, Chowdhury N, Fisher M, Moonis M. Use of telemedicine to increase thrombolysis and advance care in acute ischemic stroke. Cerebrovasc Dis. 2009; 27 Suppl 4:9-14.
|
|
|
|
|
12.
|
Evans BA, Evans JE, Baker SP, Kane K, Swearer J, Hinerfeld D, Caselli R, Rogaeva E, St George-Hyslop P, Moonis M, Pollen DA. Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(6):519-24.
|
|
|
|
|
13.
|
Moonis M. Intraarterial thrombolysis within the first three hours after acute ischemic stroke in selected patients. Stroke. 2009 Jul; 40(7):2611-2.
|
|
|
|
|
14.
|
Hinerfeld DA, Moonis M, Swearer JM, Baker SP, Caselli RJ, Rogaeva E, St George-Hyslop P, Pollen DA. Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. Arch Neurol. 2007 Nov; 64(11):1672-3.
|
|
|
|
|
15.
|
Duffis EJ, Jones D, Tighe D, Moonis M. Neurological complications of coronary angiographic procedures. Expert Rev Cardiovasc Ther. 2007 Nov; 5(6):1113-21.
|
|
|
|
|
16.
|
Patel D, Moonis M. Clinical implications of aspirin resistance. Expert Rev Cardiovasc Ther. 2007 Sep; 5(5):969-75.
|
|
|
|
|
17.
|
Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007 Jun 6; 27(23):6174-84.
|
|
|
|
|
18.
|
Laxminarayan P, Alvarez SA, Ruiz C, Moonis M. Mining statistically significant associations for exploratory analysis of human sleep data. IEEE Trans Inf Technol Biomed. 2006 Jul; 10(3):440-50.
|
|
|
|
|
19.
|
Padma V, Fisher M, Moonis M. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke. Expert Rev Cardiovasc Ther. 2006 May; 4(3):405-15.
|
|
|
|
|
20.
|
Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology. 2005 Jul 26; 65(2):323-5.
|
|
|
|
|
21.
|
Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke. 2005 Jun; 36(6):1298-300.
|
|
|
|
|
22.
|
Padma V, Fisher M, Moonis M. Thrombolytic therapy for acute ischemic stroke: 3 h and beyond. Expert Rev Neurother. 2005 Mar; 5(2):223-33.
|
|
|
|
|
23.
|
Padma V, Fisher M, Moonis M. Antihypertensive medications for risk reduction of first and recurrent ischemic stroke. Expert Rev Cardiovasc Ther. 2004 Nov; 2(6):867-76.
|
|
|
|
|
24.
|
Moonis M, Fisher M. HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Expert Rev Neurother. 2004 Mar; 4(2):241-7.
|
|
|
|
|
25.
|
Moonis M, Fisher M. Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use. Expert Rev Cardiovasc Ther. 2003 Nov; 1(4):611-5.
|
|
|
|
|
26.
|
Husaini BA, Sherkat DE, Moonis M, Levine R, Holzer C, Cain VA. Racial differences in the diagnosis of dementia and in its effects on the use and costs of health care services. Psychiatr Serv. 2003 Jan; 54(1):92-6.
|
|
|
|
|
27.
|
Moonis M. Imaging in acute ischemic stroke : relevance to management. Neurol India. 2002 Dec; 50 Suppl:S30-6.
|
|
|
|
|
28.
|
Moonis M. Thrombolytic therapy for acute ischemic stroke : issues and answers. Neurol India. 2002 Dec; 50 Suppl:S50-6.
|
|
|
|
|
29.
|
Moonis M, Fisher M. Considering the role of heparin and low-molecular-weight heparins in acute ischemic stroke. Stroke. 2002 Jul; 33(7):1927-33.
|
|
|
|
|
30.
|
Moonis M, Lee B, Bailer RT, Luo Q, Montaner LJ. CCR5 and CXCR4 expression correlated with X4 and R5 HIV-1 infection yet not sustained replication in Th1 and Th2 cells. AIDS. 2001 Oct 19; 15(15):1941-9.
|
|
|
|
|
31.
|
Moonis M, Fisher M. [Imaging of acute stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2001; (Suppl 2):4-11.
|
|
|
|
|
32.
|
Moonis M, Fisher M. Imaging of acute stroke. Cerebrovasc Dis. 2001; 11(3):143-50.
|
|
|
|
|
33.
|
Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep; 182(3):766-75.
|
|
|
|
|
34.
|
Selvaraj N, Moonis M, Ravin P. Hemiparesis following influenza vaccination. Postgrad Med J. 1998 Oct; 74(876):633-5.
|
|
|
|
|
35.
|
Drachman DA, Swearer JM, Kane K, Osgood D, O'Toole C, Moonis M. The cognitive assessment screening test (CAST) for dementia. J Geriatr Psychiatry Neurol. 1996 Oct; 9(4):200-8.
|
|
|
|
|
36.
|
Moonis M, Smith TW. Meningeal gliomatosis presenting as multiple cerebral infarcts: a case report. Neurology. 1996 Jun; 46(6):1760-2.
|
|
|
|
|
37.
|
Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996 Feb; 173(2):355-64.
|
|
|
|
|
38.
|
Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, Willis KJ, Osburne MS, Profy AT, Jenson JC, Hirsch MS. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother. 1996 Jan; 40(1):234-6.
|
|
|
|
|
39.
|
Cohen RA, O'Donnell BF, Meadows ME, Moonis M, Stone WF, Drachman DA. ERP indices and neuropsychological performance as predictors of functional outcome in dementia. J Geriatr Psychiatry Neurol. 1995 Oct; 8(4):217-25.
|
|
|
|
|
40.
|
Mazzulli T, Rusconi S, Merrill DP, D'Aquila RT, Moonis M, Chou TC, Hirsch MS. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother. 1994 Apr; 38(4):656-61.
|
|
|
|
|
41.
|
Moonis M, Ahmad I, Bachhawat BK. Effect of elimination of phagocytic cells by liposomal dichloromethylene diphosphonate on aspergillosis virulence and toxicity of liposomal amphotericin B in mice. J Antimicrob Chemother. 1994 Mar; 33(3):571-83.
|
|
|
|
|
42.
|
Moonis M, Ahmad I, Bachhawat BK. Liposomal hamycin in the control of experimental aspergillosis in mice: effect of phosphatidic acid with and without cholesterol. J Antimicrob Chemother. 1993 Apr; 31(4):569-79.
|
|
|
|
|
43.
|
Moonis M, Ahmad I, Bachhawat BK. Mannosylated liposomes as carriers for hamycin in the treatment of experimental aspergillosis in Balb/C mice. J Drug Target. 1993; 1(2):147-55.
|
|
|
|
|
44.
|
Moonis M, Ahmad I, Bachhawat BK. Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin. Indian J Biochem Biophys. 1992 Aug; 29(4):339-45.
|
|
|
|
|
45.
|
Moonis M, Ahmad I, Bachhawat BK. Macrophages in host defence--an overview. Indian J Biochem Biophys. 1992 Apr; 29(2):115-22.
|
|
|
|
|
46.
|
Moonis M, Jain S, Kalra V, Ahuja GK. Local tetanus initially mistaken as compressive thoracic myelopathy: a case report with electrophysiological findings. Indian Pediatr. 1991 Nov; 28(11):1333-6.
|
|
|
|
|
47.
|
Sachdev HP, Sachdev MS, Verma L, Sood NN, Moonis M. Electrophysiological studies of the eye, peripheral nerves and muscles in epidemic dropsy. J Trop Med Hyg. 1989 Dec; 92(6):412-5.
|
|
|
|
|
48.
|
Moonis M, Gupta R, Kumar K, Bihari M, Prasad K, Goulatia RK, Ahuja GK. Proximal myopathy as a presenting feature in hyperparathyroidism. Indian Pediatr. 1988 Jul; 25(7):694-8.
|
|
|
|
|
49.
|
Moonis M, Jain S, Prasad K, Mishra NK, Goulatia RK, Maheshwari MC. Left thalamic hypertensive haemorrhage presenting as transient global amnesia. Acta Neurol Scand. 1988 Apr; 77(4):331-4.
|
|
|
|
|
50.
|
Sachdev MS, Verma L, Garg SP, Moonis M, Shekar CH, Gupta NK. Bilateral disc oedema in retinitis pigmentosa--an unusual sign. Jpn J Ophthalmol. 1987; 31(4):621-6.
|
|
|
|
